Skip to main content
. 2019 Jan 18;14(1):e0210274. doi: 10.1371/journal.pone.0210274

Fig 1. Bromelain treatment caused a reduction in the survival of colorectal cancer (CRC) cells.

Fig 1

CRC cells (HT-29, HCT116, and DLD-1) were incubated with different doses of bromelain (0~90 μg/ml) for 48 h. Cell survival rates were determined by a sulforhodamine B assay. The relative vehicle survival rate was set to 100%. Dose-dependent cytotoxic effects of bromelain are presented in the graph. The IC50 value of bromelain was around 60~70 μg/ml with 48 h of treatment. Data are presented as the mean±SD of three independent experiments run in triplicate. ** p<0.01.